Q32 Bio
Diyong Xu is a Principal on the Private Equity team at OrbiMed, covering venture capital investments in biotech, medical device and diagnostics companies. Diyong has been a board observer for Terns. He was previously a board observer for Arcutis, Imara, NextCure, Passage Bio, Repare and SpringWorks.
Prior to joining OrbiMed, Diyong worked for Lazard in Healthcare Investment Banking Group, where he focused on M&A, financing and strategic advisory for biotech, diagnostics and pharma clients in U.S., Japan and E.U.
Diyong received his M.S. in Management Science and Engineering from Stanford University, M.S. in Molecular and Cellular Biology from Dartmouth College, and B.S. in Biology from Zhejiang University.
This person is not in the org chart
This person is not in any offices
Q32 Bio
1 followers
Q32 Bio is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases.